Intellia Therapeutics, Inc. vs Pfizer, Inc. — Stock Comparison
Q·Score Breakdown
6.2
Neutral
Overall
6.5
Neutral
Quality
Health
Growth
Valuation
Sentiment
NTLA
Clean balance sheet with low leverage (0.1× debt-to-equity).
⚠ low return on equity (-53%).
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
Analyst Consensus
BUY
Target $26.71 (+101.5%)
21 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts
Fundamentals
NTLA
PFE
—
Trailing P/E
19.4×
-4.6×
Forward P/E
9.4×
0.0%
Profit Margin
12.4%
0.0%
Gross Margin
75.8%
-53.5%
ROE
8.9%
78.8%
Revenue Growth
-1.2%
—
Earnings Growth
—
1.99
Beta
0.39
—
Price / Book
—
$1.6B
Market Cap
$149.8B
$7 – $28
52-Week Range
$22 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →